secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001564590-21-040793
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics reports Q2 2021 results; first patient dosed with FT819 iPSC CAR T-cell therapy
--------------------------------------------------------------------------------

- Q2 2021 revenue $13.4M from collaborations; R&D expenses $48.0M; cash & investments $845.1M.
- First patient treated in Phase 1 trial of FT819, first-ever iPSC-derived CAR T-cell therapy, for ALL.
- FT516 interim data at ASCO: 8/11 patients (73%) objective response, 6 complete responses in B-cell lymphoma.
- FT538 Phase 1 in AML: 2 patients evaluable, 1 achieved CRi; dose escalation ongoing.
- Appointed Dr. Mark Plavsic as Chief Technical Officer and Dr. Yuan Xu to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000156459021040793/0001564590-21-040793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000156459021040793/fate-8k_20210804.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-040793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer